Doctor/Provider Profile

Charlie B. Strange, M.D., FCCP

Provider Image
  • Professor
Degree M.D., FCCP
School M.D. awarded by Medical College of Virginia, 1982
  • Medical University of South Carolina
  • Medical University of South Carolina
Board Certification
  • Internal Medicine
  • Internal Medicine: Critical Care Medicine
  • Internal Medicine: Pulmonary Disease
  • Pulmonary & Critical Care Medicine
Clinical Interests
  • Alpha-1 antitrypsin deficiency
  • Interstitial lung diseases
  • Pleural diseases
  • Pulmonary hypertension
  • Scleroderma
  • English
Accepts New Patients Yes
To request an appointment call our representatives at 843-792-1414


Rutledge Tower
135 Rutledge Ave.
Charleston, SC 29425
Map & Directions


Dr. Charlie Strange is a Professor of Pulmonary and Critical Care Medicine at MUSC with faculty appointments in the Department of Medicine and the Department of Graduate Studies. His clinical interests include chronic obstructive pulmonary disease (with specialty interest in alpha-1 antitrypsin deficiency and bronchoscopic lung volume reduction) and interstitial lung disease (with specialty interest in the connective tissue diseases).

Dr. Strange is the Principal Investigator for the NIH Rare Lung Disease Consortium at MUSC that will study CT lung densitometry in alpha-1 antitrypsin deficiency, the efficacy and safety of rapamycin in lymphangioleiomyomatosis (LAM), and macrophage functioning in alveolar proteinosis. This NIH program seeks to establish centers of excellence that can be extended to study other rare diseases.

Dr. Strange also is the Principal Investigator for the Alpha-1 Foundation Research Registry, the largest registry of individuals with alpha-1 antitrypsin deficiency or the carrier state in the world. The Registry is used to support research on new therapies, genetic linkage studies, and social sciences research.  The Alpha Coded Testing (ACT) study provides confidential testing for alpha-1 antitrypsin deficiency.

Connective tissue disease studies in collaboration with the Division of Rheumatology include the Scleroderma Lung Study, a prospective evaluation of cyclophosphamide vs. placebo for scleroderma interstitial lung disease. Dr. Strange is an active investigator in the MUSC pulmonary hypertension center and its associated clinical trials.

Dr. Strange is available for physician consultations on the above research studies and continues active inpatient and outpatient clinical service. For this activity and teaching he has been listed in “Best Doctors in America” 2003-2006 for General Pulmonary and Critical Care Medicine, Interstitial Lung Diseases, and Chronic Obstructive Pulmonary Disease. In 2006 he was a MUSC Medical Student Faculty Excellence Award nominee.

Multimedia Library


Saving Breath: Diagnosing and Managing COPD

Edit Profile